Medigen Biotechnology Stock Shares Owned By Institutions
| 3176 Stock | TWD 34.60 0.15 0.44% |
Medigen Biotechnology fundamentals help investors to digest information that contributes to Medigen Biotechnology's financial success or failures. It also enables traders to predict the movement of Medigen Stock. The fundamental analysis module provides a way to measure Medigen Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigen Biotechnology stock.
Medigen |
Medigen Biotechnology Company Shares Owned By Institutions Analysis
Medigen Biotechnology's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Medigen Biotechnology Shares Owned By Institutions | 2.80 % |
Most of Medigen Biotechnology's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigen Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 2.8% of Medigen Biotechnology are shares owned by institutions. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares owned by institutions for all Taiwan stocks is notably lower than that of the firm.
Medigen Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigen Biotechnology's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medigen Biotechnology could also be used in its relative valuation, which is a method of valuing Medigen Biotechnology by comparing valuation metrics of similar companies.Medigen Biotechnology is currently under evaluation in shares owned by institutions category among its peers.
Medigen Fundamentals
| Return On Equity | -0.0022 | |||
| Return On Asset | 0.0036 | |||
| Profit Margin | (0.08) % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 2.9 B | |||
| Shares Outstanding | 139.45 M | |||
| Shares Owned By Insiders | 25.17 % | |||
| Shares Owned By Institutions | 2.80 % | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 1.66 X | |||
| Revenue | 3.92 B | |||
| Gross Profit | 2.55 B | |||
| EBITDA | 1.35 B | |||
| Net Income | (52.61 M) | |||
| Total Debt | 470.77 M | |||
| Book Value Per Share | 18.24 X | |||
| Cash Flow From Operations | 518.12 M | |||
| Earnings Per Share | (0.51) X | |||
| Number Of Employees | 18 | |||
| Beta | 0.99 | |||
| Market Capitalization | 4.42 B | |||
| Total Asset | 8.2 B | |||
| Z Score | 5.4 | |||
| Net Asset | 8.2 B |
About Medigen Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigen Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigen Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigen Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medigen Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medigen Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Medigen Stock
| 0.72 | 2881A | Fubon Financial Holding | PairCorr |
| 0.62 | 2891B | CTBC Financial Holding | PairCorr |
| 0.54 | 2891 | CTBC Financial Holding | PairCorr |
| 0.53 | 2882B | Cathay Financial Holding | PairCorr |
The ability to find closely correlated positions to Medigen Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medigen Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medigen Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medigen Biotechnology to buy it.
The correlation of Medigen Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medigen Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medigen Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medigen Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medigen Stock Analysis
When running Medigen Biotechnology's price analysis, check to measure Medigen Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Biotechnology is operating at the current time. Most of Medigen Biotechnology's value examination focuses on studying past and present price action to predict the probability of Medigen Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Biotechnology's price. Additionally, you may evaluate how the addition of Medigen Biotechnology to your portfolios can decrease your overall portfolio volatility.